Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine

Pang,Yanbin; Geng,Suxia; Zhang,Hongyang; Lai,Peilong; Liao,Pengjun; Zeng,Lingji; Lu,Zesheng; Weng,Jianyu; Du,Xin

doi:10.3892/ol.2019.10788

Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine

Authors:
- Yanbin Pang
- Suxia Geng
- Hongyang Zhang
- Peilong Lai
- Pengjun Liao
- Lingji Zeng
- Zesheng Lu
- Jianyu Weng
- Xin Du
View Affiliations

Affiliations: The Second School of Clinical Medical, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Hematology, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China
Published online on: September 3, 2019 https://doi.org/10.3892/ol.2019.10788
Pages: 4457-4466
Copyright: © Pang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) derived from myelodysplastic syndromes (MDSs) have been demonstrated to accelerate the progression of MDS. However, whether the phenotype of MSCs derived from MDS (MDS‑MSCs) may be reversed and serve as a potential target for the treatment of MDS remains unclear. The present study investigated the functional alternations of MDS‑MSCs following in vitro decitabine‑treatment. Primary MSCs were cultured from the bone marrow aspirates of 28 patients with MDS. The impact on the growth of MDS‑MSCs treated with decitabine was analyzed using the MTT assay. Changes in the gene expression levels of runt related transcription factor 2 (RUNX2), Sp7 transcription factor (SP7), cyclin dependent kinase inhibitor 1A (CDKN1A) and CD274 in MDS‑MSCs following treatment with decitabine were analyzed by reverse transcription‑quantitative polymerase chain reaction. The effects of decitabine on apoptosis and the cell cycle were examined using flow cytometry. The effect of decitabine on the immune regulation of MDS‑MSCs was tested by the co‑culture of MSCs with activated T cells in vitro. The results revealed that proliferation, apoptosis and the mRNA expression levels of RUNX2 and SP7 in MDS‑MSCs did not significantly change following treatment with decitabine compared with control MDS‑MSCs. However, treatment with decitabine resulted in a smaller population of cells in the G1 phase and an increase in the number of cells in the G2/M phase compared with control MDS‑MSCs. This change was associated with decreased expression of CDKN1A in cells treated with decitabine compared with control cells. Notably, the ability of MDS‑MSCs treated with decitabine to induce the differentiation of T cells into regulatory T cells was significantly reduced compared with control MDS‑MSCs. This was associated with a decreased expression of CD274 in MDS‑MSCs treated with decitabine compared with control MDS‑MSCs. In conclusion, the phenotype of MSCs derived from patients with MDS was partially reversed by treatment with decitabine, presenting a potential therapeutic intervention.

View Figures

View References

1	Adès L, Itzykson R and Fenaux P: Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
2	Shastri A, Will B, Steidl U and Verma A: Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 129:1586–1594. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ferrer RA, Wobus M, List C, Wehner R, Schönefeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M, et al: Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulatedbylenalidomide. Haematologica. 98:1677–1685. 2013. View Article : Google Scholar : PubMed/NCBI
4	Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, et al: Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establisha transplantable stem cell niche disease unit. Cell Stem Cell. 14:824–837. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, Hoogenboezem RM, Bindels EMJ, Adisty MN, Van Strien PMH, et al: Mesenchymal inflammation drives genotoxic stressin hematopoietic stem cells and predicts diseaseevolution in human pre-leukemia. Cell Stem Cell. 19:613–627. 2016. View Article : Google Scholar : PubMed/NCBI
6	Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, et al: Bone progenitor dysfunction induces myelodysplasia andsecondary leukemia. Nature. 464:852–857. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Chen X, Cao W and Shi Y: Plasticity of mesenchymal stem cells inimmunomodulation: Pathological andtherapeutic implications. Nat Immunol. 15:1009–10016. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL and Teicher BA: Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol. 34:619–627. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhao Y, Wu D, Fei C, Guo J, Gu S, Zhu Y, Xu F, Zhang Z, Wu L, Li X and Chang C: Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. Haematologica. 100:194–204. 2015. View Article : Google Scholar : PubMed/NCBI
10	Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, et al: Insufficient stromal support in MDS results from molecular andfunctional deficits of mesenchymal stromal cells. Leukemia. 27:1841–1851. 2013. View Article : Google Scholar : PubMed/NCBI
11	Pang Y, Deng C, Geng S, Weng J, Lai P, Liao P, Zeng L, Lu Z, Zhang J and Du X: Premature exhaustion of mesenchymal stromal cellsfrom myelodysplastic syndrome patients. Am J Transl Res. 9:3462–3468. 2017.PubMed/NCBI
12	Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, Galanopoulos A, Kotsianidis I, Kastrinaki MC and Papadaki HA: Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal wnt signaling pathway. Stem Cells Dev. 23:1568–1581. 2014. View Article : Google Scholar : PubMed/NCBI
13	Falconi G, Fabiani E, Fianchi L, Criscuolo M, Raffaelli CS, Bellesi S, Hohaus S, Voso MT, D'Alò F and Leone G: Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Exp Hematol. 44:75–83.e1-4. 2016. View Article : Google Scholar : PubMed/NCBI
14	Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al: DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 162:961–973. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chiba N, Furukawa K, Takayama S, Asari T, Chin S, Harada Y, Kumagai G, Wada K, Tanaka T, Ono A, et al: Decreased DNA methylation in the promoter region of the WNT5A and GDNF genes may promote the osteogenicity of mesenchymal stemcells from patients with ossified spinal ligaments. J Pharmacol Sci. 127:467–473. 2015. View Article : Google Scholar : PubMed/NCBI
16	Teklemariam T, Purandare B, Zhao L and Hantash BM: Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem cells. Biochem Biophys Res Commun. 452:753–759. 2014. View Article : Google Scholar : PubMed/NCBI
17	Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification ofmyeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
18	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI
19	Fei C, Zhao Y, Guo J, Gu S, Li X and Chang C: Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway inmyelodysplastic syndromes. Eur J Haematol. 93:476–486. 2014. View Article : Google Scholar : PubMed/NCBI
20	Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
21	Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L and Yu L: Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 8:e705222013. View Article : Google Scholar : PubMed/NCBI
22	Ding K, Fu R, Liu H, Nachnani DA and Shao ZH: Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. Oncol Lett. 11:2347–2352. 2016. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Armand P: Immune checkpoint blockade in hematologic malignancies. Blood. 125:3393–3400. 2015. View Article : Google Scholar : PubMed/NCBI
25	Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 169:3612017. View Article : Google Scholar : PubMed/NCBI
26	Shin DY, Sung Kang H, Kim GY, Kim WJ, Yoo YH and Choi YH: Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother. 67:305–311. 2013. View Article : Google Scholar : PubMed/NCBI
27	Shang D, Han T, Xu X and Liu Y: Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling inhuman renal clear cell carcinoma. Int J Clin Exp Pathol. 8:11140–11148. 2015.PubMed/NCBI
28	Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M and Götze KS: A clinical-molecular update onazanucleoside-based therapy for thetreatment of hematologic cancers. Clin Epigenetics. 8:712016. View Article : Google Scholar : PubMed/NCBI
29	Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, et al: Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 125:249–260. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chan CK, Chen CC, Luppen CA, Kim JB, DeBoer AT, Wei K, Helms JA, Kuo CJ, Kraft DL and Weissman IL: Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature. 457:490–494. 2009. View Article : Google Scholar : PubMed/NCBI
31	Mao Z, Ke Z, Gorbunova V and Seluanov A: Replicatively senescent cells are arrested in G1 and G2 phases. Aging (Albany NY). 4:431–435. 2012. View Article : Google Scholar : PubMed/NCBI
32	Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP, Farzaneh F and Mufti GJ: CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome. Blood. 110:847–850. 2007. View Article : Google Scholar : PubMed/NCBI
33	Zhao Z, Wang Z, Li Q, Li W, You Y and Zou P: The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. PLoS One. 7:e456752012. View Article : Google Scholar : PubMed/NCBI
34	Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, et al: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 28:1280–1288. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pleyer L, Valent P and Greil R: Mesenchymal stem and progenitor cells in normaland dysplastic hematopoiesis-masters of survivaland clonality? Int J Mol Sci. 17(pii): E10092016. View Article : Google Scholar : PubMed/NCBI